Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.55 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31542472 | 1.00 | USP30 (0.55) | USP30NR1H2HPGDUSP2SMN1; SMN2 | |
| SCHEMBL27427378 | 1.00 | USP30 (0.55) | USP30NR1H2HPGDUSP2SMN1; SMN2 | |
| SCHEMBL3319022 | 1.00 | USP30 (0.55) | USP30NR1H2HPGDUSP2SMN1; SMN2 | |
| SCHEMBL3319027 | 1.00 | USP30 (0.55) | USP30NR1H2HPGDUSP2SMN1; SMN2 | |
| SCHEMBL23971373 | 0.86 | EPHX1 (0.46) | USP30NR1H2HPGDUSP2SMN1; SMN2 | |
| SCHEMBL29187845 | 0.86 | EPHX1 (0.46) | USP30NR1H2HPGDUSP2SMN1; SMN2 | |
| SCHEMBL2281041 | 0.86 | HPGD (0.48) | USP30HPGDUSP2SMN1; SMN2RECQL | |
| SCHEMBL18502915 | 0.86 | HPGD (0.48) | USP30HPGDUSP2SMN1; SMN2RECQL | |
| SCHEMBL29187846 | 0.86 | EPHX1 (0.46) | USP30NR1H2HPGDUSP2SMN1; SMN2 | |
| SCHEMBL27427859 | 0.86 | HPGD (0.48) | USP30HPGDUSP2SMN1; SMN2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4674484-A2 | THIENOPYRROLE COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4291562-B1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20240217990-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240124474-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2024-04-18 | — | — | US | disclosed |
| EP-4291562-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-12-20 | — | — | EP | disclosed |
| US-11834453-B2 | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-12-05 | — | — | US | disclosed |
| CN-116783202-A | Thienopyrrole compounds | 吉利德科学公司 | 2023-09-19 | — | — | CN | disclosed |
| US-20230023851-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2022173722-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834453-B2 | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors | ERBB2, EGFR, ERBB3 | USP30 4606/4885NR1H2 3524/4885HPGD 1254/4885 |
| US-20240217990-A1 | THIENOPYRROLE COMPOUNDS | SSB, TPMT, LCP2 | USP30 4555/4885NR1H2 1364/4885HPGD 328/4885 |
| US-20240124474-A1 | HER2 MUTATION INHIBITORS | ERBB2, EGFR, ERBB3 | USP30 4298/4885NR1H2 1885/4885HPGD 2508/4885 |
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | USP30 59/4885NR1H2 2957/4885HPGD 4434/4885 |
| US-20230023851-A1 | HER2 MUTATION INHIBITORS | ERBB2, EGFR, ERBB3 | USP30 4298/4885NR1H2 1885/4885HPGD 2508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.